Reviewing Neuroderm (NDRM) and Dynavax Technologies (DVAX)

Neuroderm (NASDAQ: NDRM) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neuroderm and Dynavax Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuroderm 0 3 5 0 2.63
Dynavax Technologies 0 0 5 0 3.00

Neuroderm presently has a consensus price target of $45.86, suggesting a potential upside of 18.04%. Dynavax Technologies has a consensus price target of $28.00, suggesting a potential upside of 49.33%. Given Dynavax Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe Dynavax Technologies is more favorable than Neuroderm.

Profitability

This table compares Neuroderm and Dynavax Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuroderm N/A -44.69% -42.41%
Dynavax Technologies -1,177.60% -65.97% -59.47%

Valuation and Earnings

This table compares Neuroderm and Dynavax Technologies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neuroderm N/A N/A N/A ($2.12) -18.33
Dynavax Technologies $11.04 million 102.92 -$112.44 million ($1.95) -9.62

Neuroderm has higher earnings, but lower revenue than Dynavax Technologies. Neuroderm is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.4% of Neuroderm shares are held by institutional investors. Comparatively, 70.6% of Dynavax Technologies shares are held by institutional investors. 2.9% of Dynavax Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Dynavax Technologies beats Neuroderm on 6 of the 9 factors compared between the two stocks.

Neuroderm Company Profile

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson’s disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Receive News & Ratings for Neuroderm Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuroderm Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.